Novo's CagriSema setback may shift investor focus to M&A strategy, analysts say

Feb 23 (Reuters) - Novo Nordisk's next-generation weight-loss drug CagriSema was less effective than Eli Lilly's Zepbound in ...
Fierce Biotech

Novo's CagriSema loses phase 3 battle with Lilly's Zepbound, knocking 15% off share price

Novo Nordisk’s GLP-1/amylin combo has failed to beat Eli Lil | Novo Nordisk’s GLP-1/amylin combo has failed to beat Eli Lilly ...

Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved

CagriSema achieved 23% weight loss after 84 weeks of treatmentCagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84 ...
BioSpace

Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test

Head-to-head trials are often reserved for approved therapies as drugmakers try to one-up each other to gain further market share. In this case, Novo Nordisk ran the test at the candidate stage, and ...
MPR

REDEFINE 4: CagriSema Weight Loss Results Compared With Tirzepatide

The REDEFINE 4 trial evaluated weight loss outcomes for CagriSema vs tirzepatide in over 800 adults with obesity through week 84.

Novo Nordisk: Can't Ignore It At These Valuations (Rating Upgrade)

Novo Nordisk is deeply undervalued, trading at distressed multiples despite a robust pipeline and strong financials. Learn ...

VIEW Novo's CagriSema setback may shift investor focus to M&A strategy, analysts say

Novo Nordisk's next-generation weight-loss drug CagriSema was less effective than Eli Lilly's Zepbound in a head-to-head trial, a fresh blow to the Danish drugmaker's efforts to reclaim its early lead ...
BioSpace

Novo Leans Into Oral Route With Weight Loss Partnership Worth up to $2.1B

After its next-generation obesity asset CagriSema lost a head-to-head matchup with Eli Lilly’s Zepbound, Novo Nordisk is ...